MapLight (NASDAQ: MPLT) director sells shares to cover RSU tax bill

Rhea-AI Filing Summary

MapLight Therapeutics director Robert C. Malenka reported an open‑market sale of 12,116 shares of Voting Common Stock to cover tax obligations tied to restricted stock unit settlements. The weighted average sale price was $18.21 per share, with individual trades ranging from $18.00 to $18.59.

After this transaction, he held 339,254 shares directly and 31,672 shares indirectly through the Robert C. Malenka Living Trust, where he serves as sole trustee with voting and dispositive power. Shares retained by him remain subject to a 180‑day lock‑up following the October 26, 2025 final prospectus for the company’s initial public offering.

Insights

Equity compensation and insider-trading analyst

Sale is tax-related and leaves a substantial continuing stake.

The reported transaction shows Robert C. Malenka selling 12,116 shares of MapLight Therapeutics Voting Common Stock at a weighted average of $18.21 per share. Footnotes state the sale was specifically to cover tax obligations from restricted stock unit settlements, indicating it is compensation-related rather than a discretionary portfolio move.

Following the sale, he still holds 339,254 shares directly and 31,672 shares indirectly via the Robert C. Malenka Living Trust, where he has voting and dispositive power. The filing also notes that securities retained by him remain subject to a 180‑day lock‑up after the October 26, 2025 IPO final prospectus, which constrains additional sales except under permitted exceptions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Malenka Robert C.

(Last) (First) (Middle)

C/O MAPLIGHT THERAPEUTICS, INC.

800 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MapLight Therapeutics, Inc. [ MPLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Voting Common Stock	02/13/2026		S		12,116(1)	D	$18.21(2)	339,254	D
Voting Common Stock								31,672	I	See footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents sales of shares of common stock by the Reporting Person to cover tax obligations in connection with the settlement of restricted stock unit awards. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025.

2. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The shares are held by the Robert C. Malenka Living Trust U/A DTD 08/21/2012, of which the Reporting Person is the sole trustee and has voting and dispositive power.

	/s/ Kristopher L. Hanson, Attorney-in-Fact	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did MapLight Therapeutics (MPLT) director Robert C. Malenka do in this Form 4?

Robert C. Malenka sold 12,116 shares of MapLight Therapeutics Voting Common Stock in open-market transactions. The sale was executed at a weighted average price of $18.21 per share, specifically to cover tax obligations arising from the settlement of restricted stock unit awards.

At what prices were the MPLT shares sold in Robert C. Malenka’s Form 4 filing?

The sale used a weighted average price of $18.21 per share. Individual trades occurred in multiple transactions at prices ranging from $18.00 to $18.59, inclusive, with the reporting person offering to provide full trade breakdown details upon request to interested parties.

How many MapLight Therapeutics (MPLT) shares does Robert C. Malenka hold after this Form 4?

After the reported sale, Robert C. Malenka holds 339,254 MPLT shares directly. He also has indirect ownership of 31,672 shares through the Robert C. Malenka Living Trust, where he is the sole trustee with both voting and dispositive power over those trust-held shares.

Why did Robert C. Malenka sell MPLT shares according to the Form 4 footnotes?

The footnotes state the shares were sold to cover tax obligations linked to the settlement of restricted stock unit awards. Each restricted stock unit represents a contingent right to receive one MPLT share, and the sale proceeds help satisfy the associated tax liabilities for these equity awards.

What does the Form 4 say about Robert C. Malenka’s lock-up on MPLT shares?

The filing notes that MPLT securities retained by Robert C. Malenka remain subject to a lock-up agreement. Under this agreement, he agreed not to directly or indirectly sell or transfer securities for 180 days after the October 26, 2025 final prospectus for MapLight Therapeutics’ initial public offering.

How are Robert C. Malenka’s indirect MPLT holdings structured in this Form 4?

Indirect holdings are owned through the Robert C. Malenka Living Trust U/A DTD 08/21/2012. The Form 4 footnote explains he is the sole trustee of this trust and has both voting and dispositive power over the 31,672 MapLight Therapeutics shares held in the trust.